Latest Content

Trastuzumab pamirtecan produced durable responses and encouraging survival in HER2-expressing endometrial cancer after prior therapy.

The B7-H4–targeted antibody-drug conjugate produced confirmed response rates of 62% in PROC and 67% in endometrial cancer at the doses selected for phase 3 development.

Alicia Morgans, MD, MPH, discusses findings from ARACOG trial of the cognitive effects of darolutamide vs enzalutamide in prostate cancer.

Bulumtatug fuvedotin produced a confirmed ORR of 32.08% and a DCR of 81.13% in recurrent or metastatic cervical cancer, with no treatment-related deaths.

A retrospective analysis of 3234 patients with CLL/SLL showed that over half of those 75 to 79 years of age went on to receive second-line therapy.

Sonrotoclax plus zanubrutinib yielded deep, durable responses at the recommended phase 2 dose in relapsed/refractory MCL.

External validation of a circulating immune protein signature model confirmed its prognostic value for OS in recurrent ovarian cancer.

To figure out how to beat persister tumor cells, researchers at UCSF built a robotic system that treats thousands of mini tumors at once in the laboratory.

Experts in lung cancer gathered at an OncLive® Scientific Interchange and Workshop during the 2026 ASCO Annual Meeting to discuss HER2-mutated NSCLC.

Everett Meyer, MD, PhD, outlines ongoing research and the potential role for Orca-T in advanced hematologic malignancies.

A matching-adjusted indirect comparison showed favorable survival outcomes with zanubrutinib vs ibrutinib in treatment-naive chronic lymphocytic leukemia.

Pumitamig plus chemotherapy generated strong responses across NSCLC subtypes and PD-L1 levels with manageable safety in ROSETTA Lung-02.

Premal Thaker, MD, MS, discusses the role for CDK2 inhibition in platinum-resistant ovarian cancer.